ANXA1 and acute respiratory distress syndrome: As depicted in Figure 2(e), network pharmacology identified 514 drug targets (Supplementary File S1) of QYD intersected with 202 DEGs to generate three core targets of QYD in the treatment of SAP-associated ALI: acetaldehyde dehydrogenase 2 (ALDH2), annexin A1 (AnxA1), and intercellular cell adhesion molecule-1 (ICAM-1).